Not finding it? Sign in to also search OpenAlex live.
-
A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy2024 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Yuka Sugimoto, Eran Zimran, Yoshimitsu Shimomura, Hiroki Yamaguchi, Hans Carl Hasselbach, Jean‐Jacques Kiladjian, +14 more
2citations -
Abstract LB134: Type 1 calreticulin mutations differentially activate the IRE1α-XBP1 pathway of the unfolded protein response to drive myeloproliferative neoplasms2022 Cancer Research conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment
Juan Ibarra, Yassmin A. Elbanna, Katarzyna Kuryłowicz, Michele Ciboddo, Harrison S. Greenbaum, Nicole Arellano, +19 more
0citations -
Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies
Andrew Charles Perkins, Vincent Ribrag, William E. Shomali, Rosa María Ayala, Claire N. Harrison, Stephen T. Oh, +2 more
14citations -
MPN-556: Mutant Calreticulin-Specific Monoclonal Antibody INCA033989 Produces Molecular Responses That Correlate With Clinical Responses in Patients With Myelofibrosis2026 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment
John O Mascarenhas, Jyoti Nangalia, Claire N. Harrison, Jason R. Gotlib, Chenwei Tian, Betty Lamothe, +4 more
0citations -
MPN-481: Mutant Calreticulin-Specific Monoclonal Antibody, INCA033989, is Well Tolerated and Achieves Rapid and Sustained Hematologic and Molecular Responses in Patients With Essential Thrombocythemia2026 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment
Haris Ali, Tania Jain, Aaron Thomas Gerds, Vikas Gupta, Claire N. Harrison, Joan How, +27 more
0citations -
MPN with multiple driver clones show distinct patterns of therapy response and progression - “MPN double driver”2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Kirsi Marjaana Manz, Tina M. Schnoeder, Francesca Palandri, Filippo Branzanti, Heike Luise Pahl, Martin Grießhammer, +20 more
2citations -
Long-term outcome and risk factors for relapse after allogeneic hematopoietic stem cell transplantation in myelofibrosis: Results from a large multicenter cohort2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Julia-Annabell Georgi, Sebastian Stasik, Michael Krämer, Tobias A.W. Holderried, Jochen J. Frietsch, Stefan Klein, +18 more
0citations -
Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Vikas Gupta, John O Mascarenhas, Haris Ali, David M. Ross, Abdulraheem Yacoub, Tania Jain, +27 more
10citations -
Ropeginterferon alfa-2b in essential thrombocythemia of all risk levels ineligible for standard cytoreduction: 12-month primary endpoint analysis from the ROP-ET phase 3 study2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Jean‐Jacques Kiladjian, Alberto Álvarez‐Larrán, Konstanze Döhner
2citations -
Fedratinib in combination with CC-486, an oral hypomethylating agent, in patients with accelerated phase myelofibrosis: Results from the phase I/II famy trial2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Nadja Jaekel, Susann Schulze, Christina Zahn, Andreas Wienke, Michael Richter, Steffen Koschmieder, +5 more
1citations
17 results